UCLA imaging study suggests Alzheimer's drug may help mild memory loss

Jul 30, 2008

Alzheimer's disease is the end result of gradual, progressive brain aging. Positron emission technology (PET) scans of patients' brains typically reveal a decreased rate of metabolism, a hallmark of the disorder.

A small sample of adults with mild age-related memory loss was randomly assigned a daily placebo or Aricept, a drug that treats Alzheimer's symptoms. Both groups underwent PET brain scans before and after 18 months of treatment. The brains of people given Aricept showed an increased rate of metabolism and looked more normal than the brains of those who took the placebo. Both groups scored the same on memory tests, however, implying that PET scans may be more sensitive than neuropsychological tests in detecting drugs' effects.

The research suggests that the treatment of early symptoms of memory loss may protect the brain and help people with mild age-related memory impairment. The finding also shows how PET offers researchers a tool for tracking the effectiveness of drugs prescribed to treat age-related cognitive decline.

The findings will be presented July 30 at the "Hot Topics" poster session of the International Conference on Alzheimer's Disease 2008, hosted by the Alzheimer's Association.

Source: University of California - Los Angeles

Explore further: High penicillin prescribing could build reservoirs of resistance

add to favorites email to friend print save as pdf

Related Stories

Cloning whistle-blower: little change in S. Korea

Oct 24, 2014

The whistle-blower who exposed breakthrough cloning research as a devastating fake says South Korea is still dominated by the values that allowed science fraudster Hwang Woo-suk to become an almost untouchable ...

In Alzheimer's diagnosis, many heads better than one

Jan 26, 2011

In a marriage of two disciplines that don’t often overlap — politics and medicine — a study by Matthew Gabel, PhD, professor of political science in Arts & Sciences at Washington University ...

FDA panel sees promise in Alzheimer's imaging drug

Jan 20, 2011

(AP) -- A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians.

Recommended for you

Researchers gain new insights into hypothyroidism

9 hours ago

An international research team led by physician-scientists at Rush University Medical Center has gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.